These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1908753)

  • 21. Influence of the gonad on the degree of suppression induced by an LHRH agonist implant in the marmoset monkey.
    Lunn SF; Cowen GM; Morris KD; Fraser HM
    J Endocrinol; 1992 Feb; 132(2):217-24. PubMed ID: 1541921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent elevation of serum oestradiol levels by functional ovarian cysts despite effective pituitary desensitization with GnRH agonists.
    Jenkins JM; Anthony FW; Lee A; Masson GM; Thomas E
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):357-9. PubMed ID: 8187299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
    Lemay A; Maheux R; Jean C; Faure N
    Prog Clin Biol Res; 1986; 225():157-73. PubMed ID: 3097663
    [No Abstract]   [Full Text] [Related]  

  • 24. Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
    Hardt W; Schmidt-Gollwitzer M
    Clin Endocrinol (Oxf); 1983 Nov; 19(5):613-7. PubMed ID: 6416718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
    Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
    J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis.
    Donnez J; Nisolle-Pochet M; Clerckx-Braun F; Sandow J; Casanas-Roux F
    Fertil Steril; 1989 Jul; 52(1):27-30. PubMed ID: 2501110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buserelin acetate implants in the treatment of pain in endometriosis.
    Choktanasiri W; Rojanasakul A
    J Med Assoc Thai; 2001 May; 84(5):656-60. PubMed ID: 11560214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF.
    Ravhon A; Lavery S; Michael S; Donaldson M; Margara R; Trew G; Winston R
    Hum Reprod; 2000 Nov; 15(11):2297-301. PubMed ID: 11056122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols.
    Lipitz S; Ben-Rafael Z; Dor J; Shalev J; Elenbogen A; Levran D; Serr DM; Mashiach S
    Gynecol Obstet Invest; 1989; 28(1):31-4. PubMed ID: 2528497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum inhibin as an index of ovarian function in women undergoing pituitary suppression and ovarian stimulation in an in vitro fertilization program.
    Matson PL; Morris ID; Sun JG; Ibrahim ZH; Lieberman BA
    Horm Res; 1991; 35(5):173-7. PubMed ID: 1802818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.
    Lemay A; Maheux R; Huot C; Blanchet J; Faure N
    Am J Obstet Gynecol; 1988 Feb; 158(2):233-6. PubMed ID: 3124618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pituitary-gonadal suppression with a gonadotrophin-releasing hormone agonist on fetal gonadotrophin secretion, fetal gonadal development and maternal steroid secretion in the sheep.
    Thomas GB; McNeilly AS; Gibson F; Brooks AN
    J Endocrinol; 1994 May; 141(2):317-24. PubMed ID: 8046302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome.
    Macleod AF; Wheeler MJ; Gordon P; Lowy C; Sönksen PH; Conaglen JV
    J Endocrinol; 1990 May; 125(2):317-25. PubMed ID: 2115566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
    Lockwood GM; Pinkerton SM; Barlow DH
    Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of pharmacological hypogonadotropism using gonadotropin-releasing hormone agonists in patients undergoing controlled ovarian stimulation.
    Lindner C; Braendle W; Lichtenberg V; Bettendorf G
    Gynecol Obstet Invest; 1990; 29(2):132-9. PubMed ID: 2139863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Faure N; Lemay A
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.